Free Trial
NASDAQ:CRDF

Cardiff Oncology Q3 2024 Earnings Report

Cardiff Oncology logo
$2.12 +0.09 (+4.17%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiff Oncology EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Cardiff Oncology Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.13 million
Beat/Miss
Beat by +$40.00 thousand
YoY Revenue Growth
N/A

Cardiff Oncology Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Cardiff Oncology's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Cardiff Oncology Earnings Headlines

Wall Street laughed at Trump’s “Smart Dollar.” Now they’re all in.
"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the White House just greenlit a $30 trillion upgrade to our financial system. Big firms like JP Morgan and Goldman Sachs are already onboard. And our Wall Street insider expects this change to create more wealth in the next 5 years than major innovations like the computer.tc pixel
Cardiff Oncology (CRDF) Q2 Loss Down 19%
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors.

Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.

View Cardiff Oncology Profile

More Earnings Resources from MarketBeat